No Data
H.C. Wainwright Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $6
Promising Pipeline and Strategic Advances Support Buy Rating for Elevation Oncology
Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate
Express News | Synaffix: Co Is Eligible to Receive up to $368 Mln in Upfront and Clinical, Regulatory, and Commercial Milestone Payments
Express News | Elevation Oncology Inc: Expects to Present Eo-1022 Preclinical Data in 1H 2025 and to File an Ind Application in 2026
Express News | Elevation Oncology Expands Pipeline With Nomination of Eo-1022, a Her3 ADC for the Treatment of Her3-Expressing Solid Tumors
No Data
